Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
The documentation for combined immunodeficiency, X-linked, is limited primarily due to its rarity and the complexity of its clinical presentation. This condition affects a small number of individuals, making large-scale clinical studies challenging. Additionally, the genetic basis was only recently identified, which has hindered comprehensive clinical characterization. As research continues, we hope to gain better insights into this condition and improve care strategies.
The primary clinical features of combined immunodeficiency, X-linked, include severe combined immunodeficiency, characterized by a lack of functional T and B lymphocytes, leading to increased vulnerability to infections. Patients typically present with recurrent infections, particularly from opportunistic pathogens such as Pneumocystis jirovecii, which can lead to pneumonia. The onset of symptoms often occurs in infancy, and without treatment, the condition can be life-threatening. Management strategies focus on preventing infections and may include immunoglobulin therapy and hematopoietic stem cell transplantation.
To navigate your care effectively, it is essential to consult with a specialist in immunology or a pediatric immunologist, particularly one with experience in X-linked immunodeficiencies. Genetic counseling can also provide valuable insights into the implications of the IL2RG gene variant for you and your family. Additionally, consider exploring resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. Although there are no specific patient organizations identified for this condition, participating in clinical trials may also provide additional support and information.
Currently, there are 30 active clinical trials focusing on combined immunodeficiency, X-linked. These trials are exploring various treatment options and management strategies, which may provide new insights into effective therapies. You can find more information about these studies at ClinicalTrials.gov by searching for 'combined immunodeficiency, X-linked'. Participation in these trials may offer access to cutting-edge therapies and contribute to the understanding of this rare condition.
Actionable guidance for navigating care for combined immunodeficiency, X-linked
To navigate your care effectively, it is essential to consult with a specialist in immunology or a pediatric immunologist, particularly one with experience in X-linked immunodeficiencies. Genetic counseling can also provide valuable insights into the implications of the IL2RG gene variant for you and your family. Additionally, consider exploring resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further information and support. Although there are no specific patient organizations identified for this condition, participating in clinical trials may also provide additional support and information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.